J&J sues Amgen over cancer drug sales tactics

10/14/2005 | NYTimes.com

Johnson & Johnson filed an antitrust suit alleging Amgen used sales tactics to force cancer clinics to buy its Aranesp rather than J&J's Procrit, drugs used to treat chemotherapy-related anemia. The suit notes U.S. sales of the two drugs are expected to reach $2.8 billion this year. An Amgen spokeswoman said, "We believe the allegations are not legitimate and we intend to fight this."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA